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Chemo- or radiation-resistance in tumors caused by hypoxia often undermines efﬁcacy of cancer
therapy. Thus, therapies that overcome cellular resistance during hypoxia are necessary. SM22a is
an actin-binding protein found in smooth muscle, ﬁbroblasts, and some epithelium. We demon-
strate that SM22a is induced in A549 non-small cell lung carcinoma cells by hypoxia and its overex-
pression increased chemo- and radiation-resistance. Hypoxia-mediated induction of SM22a
expression is hypoxia-inducible factor-independent. Moreover, SM22a overexpression enhances
tumor cell growth and activates the IGF1R/PI3K/Akt pathway via direct interaction with IGF1Rb.
Our results suggest SM22a as a novel regulator of hypoxic survival pathway of A549 NSCLC cells.
Structured summary of protein interactions:
IGFR1 Beta physically interacts with SM22 alpha by anti bait coimmunoprecipitation (View Interaction:
1, 2)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction sitotide-3-kinase (PI3K) [4], extracellular signal-regulated kinaseCells in rapidly growing tumors quickly outstrip the vascular
supply, resulting in a poorly vascularized microenvironment char-
acterized by hypoxia and nutrient starvation [1]. The hypoxic sta-
tus of various solid tumors has been linked to poor prognosis due
to tumor progression toward a more malignant phenotype, with an
increased resistance to radiotherapy and chemotherapy treatment
[2]. The best characterized hypoxia response pathway is mediated
by hypoxia-inducible factor (HIF), a heterodimeric DNA-binding
complex composed of two basic helix-loop-helix proteins, namely
the constitutive HIF-1b and one of either hypoxia-inducible a-
subunits, HIF-1a or HIF-2a [3]. HIF regulates the expression of
more than 70 genes, including proapoptotic and antiapoptotic
ones, and is considered as a master regulator of the hypoxic re-
sponse. However, accumulating evidence indicates that HIF-inde-
pendent pathways also promote cell survival and control
angiogenesis under hypoxic conditions by activating phosphoino-chemical Societies. Published by E
ptor; HIF, hypoxia-inducible
tor; IgG, immunoglobulin G;
thanesulfonate; NSCLC, non-
e-3-kinase; RT-PCR, reverse
nescence-associated b-galac-
).1/2 [5], or p38 mitogen-activated protein kinase [6].
SM22a, which is also called as transgelin, is a shape change-
sensitive actin cross-linking/gelling protein found in ﬁbroblasts
and smooth muscle [7]. It is a member of the calponin family,
which is localized to the cytoskeletal apparatus [8]. SM22a-null
mice reveal that SM22a is involved in calcium-independent
smooth muscle contraction [9]. Recently, different functions for
SM22a are suggested such as a tumor suppressor [10]. Also, our
previous studies revealed that SM22a is involved in cellular resis-
tance against anti-cancer drugs or gamma-radiation [11] and in
cellular senescence [12].
Here, we present another function of SM22a in A549 non-small
cell lung carcinoma (NSCLC) cells. In A549 cells exposed to hypoxic
stress SM22a protein levels were elevated, which increased the
cell growth and cellular-resistance against anti-cancer drugs and
gamma-radiation. Interestingly, hypoxic induction of SM22a in
these cells was independent of HIF-1a and activated the insulin-
like growth factor receptor (IGFIR)/PI3K/Akt signal pathway via di-
rect interaction between SM22a and IGF1Rb.
2. Materials and methods
2.1. Cell culture, chemicals, gamma-radiation and transfection
Human NSCLC A549 cells were obtained from the American
Type Culture Collection (Manassas, VA, USA) and cultured inlsevier B.V. All rights reserved.
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with 2 mM glutamine, 10% (v/v) fetal bovine serum (Invitrogen),
100 U/ml of penicillin, and 100 lg/ml of streptomycin (Invitrogen)
at 37 C in a 5% CO2 humidiﬁed incubator. Methyl methanesulfo-
nate (MMS), cis-platinum (II)–diamine dichloride (Cisplatin),
H2O2, and cobalt chloride (CoCl2), were purchased from Sigma–
Aldrich (St. Louis, MO, USA). AG1024 was purchased from Calbio-
chem (La Jolla, CA, USA). Prior to gamma-radiation, cells were
seeded into T25 ﬂasks at 1  106 cells/ﬂask. On the next day, the
cells were exposed to a single dose of 20 Gy (60Co c-ray source;
dose rate, 2 Gy/min) and cultured for the indicated time periods.
SM22a-expression vectors and silencing RNA (siRNA) targeting of
SM22a were used as described previously [12].
2.2. Hypoxic exposure of lung carcinoma cells
Cells were seeded in 100-mm dishes and grown until conﬂu-
ence. Cells were then subjected to hypoxia (1% O2) by placing them
in an Innova Co-48 hypoxia incubator (New Brunswick Scientiﬁc,
Edison, NJ, USA). The incubator was evacuated until the desired
oxygen partial pressure was reached and then replenished with a
gaseous mixture containing 5% CO2 and 95% N2. The cells were
incubated within the chamber at 37 C for up to 24 h.
2.3. Western blot and RT PCR analysis
Protein extraction and Western blotting were performed as de-
scribed previously [13] using primary antibodies speciﬁc for hu-Fig. 1. Hypoxic stress increases SM22a in A549 NSCLC cells. (A) SM22a protein levels
cisplatin (0.02 or 0.2 mM), or MMS (0.05 or 0.5 mM) for 6 h. (B) SM22a or HIF-1a protein
HIF-1a and SM22a protein levels were analyzed in A549 cells treated with a hypoxia-mim
in A549 cells transfected with SM22a expression vector (SM22a (+)) for 48 h. As transfe
A549 cells depleted of HIF-1a by RNA interference (siSM22a) when exposed to hypoxi
normoxia were compared as control (Ctl). Cells transfected with siRNA control (siCtl) we
protein loading.man SM22a (Abcam, London, UK), HIF-1a, PI3 K p110,
phosphatase and tensin homolog (PTEN), K-Ras (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), phospho-Akt (Ser473), Akt, phos-
pho- epidermal growth factor receptor (EGFR [Tyr1068]), EGFR,
phospho-IGF1Rb (Tyr1131)/insulin receptor b (Tyr1146), IGF1Rb
(111A9; Cell Signaling Technology, Danvers, MA, USA), and the cor-
responding secondary antibodies. RT-PCR analysis of SM22a was
performed as described previously [12].
2.4. Measurement of cell death and colony forming assay
Cell deathwasmeasured by sub-G1/G0 phase analysis of propidi-
um iodide-stained cells using the Epics XL ﬂow cytometer (Beckman
Coulter Counter, Fullerton, CA, USA), as described previously [14].
Colony forming assay was performed as described previously [12].
2.5. Senescence-associated b-galactosidase (SA-b-Gal) activity
staining
SA-b-Gal activity staining was performed using bromo-4-
chloro-3-indolyl-b-D-galactosidase, as described previously [15]
and a percentage of positively stained cells were analyzed
statistically.
2.6. Immunoprecipitation
Cells were lysed in NP-40 lysis buffer (20 mM Tris, pH 7.4,
150 mM NaCl, 1% NP-40, 10% glycerol) containing protease inhibi-were analyzed in A549 cells treated with cytotoxic drugs such as H2O2 (10 mM),
levels were analyzed in A549 cells after exposing to hypoxia (1% O2) for 8 or 24 h. (C)
etic drug (0.4 mM CoCl2) for 8, 16, or 24 h. (D) HIF-1a protein levels were analyzed
ction control, pcDNA3.1 (V.C.) was used. (E) SM22a protein levels were analyzed in
a (1% O2). Hypoxic activation of AKT by phosphorylation was also showed. Cells in
re analyzed in parallel. Protein levels of b-actin were used as an internal control for
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ride, 1 mM ethylenediaminetetraacetic acid, 130 lM Bestatin,
1 lM leupeptin, 14 lM E-64, 0.3 lM Aprotinin). For immunopre-
cipitation, cell lysates containing 1 mg protein were incubated
with 1 lg anti-IGF1Rb antibody overnight at 4 C. The antibody-
protein complexes were then incubated with protein A/G plus aga-
rose beads for 2 h at 4 C, and the beads were pelleted by centrifu-
gation at 2000g for 2 min. The beads were washed three times
with lysis buffer and analyzed by Western blotting using anti-
SM22a and anti-IGF1Rb antibody. For controls of non-speciﬁc
immunoprecipitation, non-relevant rabbit IgG or anti-EGFR anti-
body were used in parallel. Cell lysates containing 20 lg proteins
were analyzed by Western blotting.
3. Results
3.1. SM22a induction in A549 NSCLC cells under hypoxic condition
Most patients with NSCLC exhibit advanced disease and multi-
drug chemotherapy resistance is common in NSCLC [16]. In our
previous studies on the chemo-resistance of HepG2 hepatocellular
carcinoma cells, we found that SM22a is induced in HepG2 cells by
cytotoxic chemicals and the overexpression of SM22a confers che-
mo- and radiation-resistance [11]. To investigate whether the che-
mo-resistance of NSCLC cells is also associated with SM22a, its
expression in A549 NSCLC cells was analyzed after treatment with
cytotoxic chemicals. As shown in Fig. 1A, treatment with a sub-
lethal dose of H2O2 increased SM22a expression. Cisplatin and
MMS, typical cytotoxic agents used in cancer treatment, also ele-
vated SM22a in a dose-dependent manner.
In clinical tumors, hypoxia also induces chemo-resistance [17].
Hypoxia protects A549 cells from drug-induced apoptosis in HIF-
dependent or independent manner [18]. Therefore, we examinedFig. 2. SM22a is associated with the cellular resistance of A549 cells. (A) SM22a- over
expressing vector, SM22a(+), or SM22a-targeted siRNA (siSM22a) for 48 h. For controls
analyzed in parallel. (B) SM22a-overexpressing A549 cells were exposed to cytotoxic r
analyzed by ﬂow cytometric analysis of propidium iodide-stained cells. Cell death indu
percentage of cell death is indicated within the plot. (C) SM22a-depleted A549 cells we
then cell death was analyzed. Effect of gamma-irradiation (20 Gy) was also analyzed
overexpressing cells to evaluate cellular senescence.whether SM22a is also involved in hypoxia-induced cellular resis-
tance of A549 cells. In A549 cells exposed to hypoxia SM22a was
accumulated in a time-dependent manner, in which HIF-1a was
also increased (Fig. 1B). To evaluate whether HIF regulates the
expression of SM22a, A549 cells were treated with cobalt chloride,
a chemical inducer of HIF-1a: however, SM22a protein levels were
not changed (Fig. 1C). Overexpression of SM22a also did not in-
crease HIF-1a (Fig. 1D), which suggests that hypoxia-inducible
SM22a is not regulated by HIF-1a and that SM22a may act as an
alternative regulator of survival pathway in hypoxia. To conﬁrm
the induction of SM22a irrespective of HIF-1a, HIF-1a-suppressed
A549 cells were exposed to hypoxia and SM22a protein levels
were analyzed. As shown in Fig. 1E, SM22a was induced by hyp-
oxic stress regardless of HIF-1a. Moreover, SM22a was more ele-
vated when HIF-1a was depleted. In these conditions AKT was
also activated with or without HIF-1a, as previously reported [19].
3.2. Protective effects of SM22a against anti-cancer drugs and gamma-
radiation in A549 cells
SM22a-overexpressing A549 cells (Fig. 2A) were challenged
with various cytotoxic agents and cell death was measured
(Fig. 2B). A sub-lethal dose of cisplatin (240 lM, 24 h) and MMS
(1 mM, 24 h) in control cells (V.C.) caused severe cell death (48%
by cisplatin and 85% by MMS); however, SM22a-overexpression
resulted in reduction of cell death to approximately 20%. Cell death
mediated by gamma-radiation was also diminished by SM22a-
overexpression (50% in control cells but 9% in SM22a-overexpress-
ing cells). These results indicate that induction of SM22a by hypox-
ia may be closely involved in cellular resistance of hypoxic cells
against cytotoxic agents. Reversely, siRNA-mediated knockdown
of SM22a sensitized the cells to a variety of damaging agents
(Fig 2C). When control cells (siCtl) were treated with cisplatinexpressing or suppressing A549 cells were prepared by transfection with SM22a-
, cells transfected with empty pcDNA3.1 vector (V.C.) or siRNA control (siCtl) were
eagents (240 lM cisplatin for 24 h, 1 mM MMS for 48 h) and then cell death was
ced by gamma-irradiation (20 Gy) was also analyzed at 72 h after irradiation. The
re exposed to cytotoxic reagents (240 lM cisplatin for 6 h, 1 mM MMS for 6 h) and
48 h after irradiation. (D) SA-b-Gal activity staining was performed on SM22a-
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11.7% or 25.4%. However, when SM22a was depleted cell death
was elevated approximately 2- or 3-fold (30.5% or 40.2%).
Chemo-resistance of HepG2 cells is associated with cellular
senescence induced by SM22a overexpression [11,12]. SM22a
overexpression severely inhibited cell growth and activated the
p16INK4a/pRB senescence signaling pathway. Moreover, the expres-
sion of several metallothionein isoforms, such as MT1G, increased
dramatically. In A549 cells, however, SM22a overexpression did
not induce cellular senescence, which was validated by SA-b-Gal
staining (Fig. 2D). In addition, the expression of metallothionein
isoforms did not change (Supplementary Fig. 1). Although SM22a
overexpression induces chemo-resistance in HepG2 and A549 cells,
its regulatory mechanisms in HepG2 and A549 cells are different.
3.3. SM22a overexpression in A549 cells activates the PI3K/Akt
pathway
In contrast to HepG2 cells, SM22a overexpression in A549 cells
increased cell growth (Fig. 3A). The colony forming ability of
SM22a-overexpressing A549 cells was higher than control cells
by approximately twofold. SM22a-knockdown resulted in the
opposite effect (Fig. 3B).
The PI3K/Akt pathway is a key regulator of cancerous growth
and induction of hypoxia-related proteins [20]. It is also associated
with radiation-resistance. Activation of this pathway can occur as a
result of stimulation of receptor tyrosine kinases, such as EGFR orFig. 3. SM22a overexpression enhances the growth of A549 cells, which is mediated by A
with SM22a-expressing or control vector. Clonogenic survival of tested cells was expresse
siRNA-targeted against SM22a, colony-forming assay was also performed. (C) Cells trans
transfection and Western blot analysis was performed on indicated proteins. A549 cells
(D) SM22a and phosphor-AKT protein levels were analyzed in A549 cells exposed to hyvascular endothelial growth factor receptor. Moreover, mutation or
overexpression of PI3K or Akt itself, which are frequently found in
NSCLC, can also lead to activation of the PI3K/Akt pathway. Be-
cause SM22awas associated with chemo- and radiation-resistance
and its overexpression stimulated cell growth in A549 cells, we
examined whether PI3K/Akt pathway is activated directly by
SM22a. Overexpression of SM22a led to accumulation of phos-
phorylated Akt and SM22a-knockdown resulted in the opposite ef-
fect (Fig. 3C). However, EGFR, a typical receptor tyrosine kinase
responsible for Akt activation, was not changed. In addition, the
levels of PI3K-p110 and K-ras, which are all upstream regulators
of Akt, were not inﬂuenced. PTEN, an inhibitor of the PI3K pathway,
was also unchanged, indicating that Akt in these cells is modulated
by other signaling molecules. Expression of components of the
PI3K/Akt pathway and SM22a were also examined in A549 cells
exposed to hypoxic conditions (Fig. 3D). In hypoxic A549 cells,
SM22a and phosphorylated Akt were elevated, while phosphory-
lated EGFR and PTEN remained unchanged as in SM22a-over-
expressing cells.
3.4. SM22a overexpression in A549 cells activates the IGF1R/PI3K/Akt
pathway by direct interaction with IGF1Rb
IGF1R is another upstream regulator of Akt and an important
receptor tyrosine kinase in NSCLC [21]. Hypoxic A549 cells, in
which SM22a was highly increased, showed dramatically elevated
phosphorylation of IGF1Rb (Fig. 4A). Hypoxic conditions lead to thekt activation. (A) Colony-forming assays were performed for A549 cells transfected
d as a percentage relative to transfection control. (B) For A549 cells transfected with
fected with control or SM22a-expressing vectors were harvested at 72 or 96 h post-
transfected with siRNA against SM22a were also analyzed at 48 h post-transfection.
poxic conditions (1% O2) for 24 h.
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tionship between increased SM22a and phosphorylation of IGF1Rb
and Akt, their phosphorylations were analyzed in SM22a-over-
expressing A549 cells. Fig. 4B shows that IGF1Rb phosphorylation
was increased only by SM22a-overexpression. Moreover, Akt acti-
vation in SM22a-overexpressing A549 cells was inhibited com-
pletely by AG1024, a speciﬁc inhibitor of IGF1R kinase activity
(Fig. 4C), which suggest that Akt activation by SM22a is mediated
by IGF1R auto-phosphorylation.
Additional evidence of activation of IGF1R by SM22a was ob-
tained using a point mutant of SM22a. While creating the
SM22a-overexpression vector, we obtained a point mutant of
SM22a gene in which the native A residue at nucleotide position
266 was changed to G (Supplementary Fig. 2). This mutation al-
tered the Lys residue (codon: AAG) at amino acid position 89 to
Glu (codon: GAG). Growth of A549 cells transfected with this
SM22a-mutant (SM22aL89E) was indistinguishable from that of
non-transfected cells. In addition, cellular resistance against cyto-
toxic chemicals or radiation was not observed in these cells (Sup-
plementary Fig. 3). SM22aL89E also did not activate Akt or IGF1Rb
phosphorylation (Fig. 4D). Based on these results, we concluded
that SM22a is important for IGF1Rb activation and Lys89 of
SM22a protein is critical for this activation.
In general, IGF1R is activated by speciﬁc ligands (e.g., IGF-I, IGF-
II) in the extracellular space. However, the activation mode of
IGF1R by SM22a, a cytoskeletal protein that interacts with actin,
may be different from that of speciﬁc ligands. One of possible acti-
vation mode is direct interaction between SM22a and the intracel-
lular domain of IGF1R, which induces auto-phosphorylation of
IGF1R. Co-immunoprecipitation of SM22a from A549 cell lysates
using an anti-IGF1Rb antibody conﬁrmed our hypothesis. As
shown in Fig 5, SM22a was co-immunoprecipitated with IGF1RbFig. 4. SM22a-overexpression in A549 cells activates the IGF1Rb/Akt pathway. (A) A549
phospho-IGF1Rb and IGF1Rb. (B) Phospho-IGF1Rb and IGF1Rb protein levels were also a
Stable transfectants of SM22a (SM22a(+)S) were treated with AG1024 at 10 lM for 24 h
mutant-expressing (SM22amut) or control vector was transfected into A549 cells for 72in SM22a-overexpressing cells and IGF1Rb was phosphorylated
(Fig. 5A). However, SM22aL89E was not co-immunoprecipitated
with IGF1Rb despite of its overexpression (Fig. 5B). Finally, we con-
ﬁrmed that hypoxia-induced SM22a was coimmunoprecipitated
with IGF1Rb, which was phosphorylated (Fig. 5C), revealing that
SM22a is directly involved in hypoxia-induced IGF1R activation.
Although the underlying activation mechanisms remain to be
identiﬁed in future studies, our ﬁndings clearly demonstrate that
SM22a overexpressed in A549 cells induces activation of the
IGF1Rb/PI3K/Akt pathway via direct interaction with IGF1Rb, lead-
ing to cellular resistance against apoptotic cell death caused by
hypoxic stress or cytotoxic agents. This study provides the ﬁrst
demonstration of hypoxic regulation of SM22a and also suggests
that SM22a is a novel regulator that positively modulates the
IGF1Rb/PI3K/Akt pathway in A549 cells.
4. Discussion
SM22a was originally isolated and characterized from chicken
gizzard smooth muscle [22] and has been established as a transfor-
mation- and cell shape-sensitive actin cross-linking/gelling protein
[7]. Human SM22a cDNA was cloned during a study that identiﬁed
genes involved in replicative senescence, and was suggested as a
marker for senescence [23]. Thus, initial studies on SM22a had fo-
cused on its functions in muscle and senescent cells. Recent studies
have revealed novel functions for SM22a in cells other than
smooth muscle or ﬁbroblasts. SM22a has been identiﬁed as the
ﬁrst ARA54-associated negative modulator for androgen receptor
in prostate cells [24]. The mitochondria-associated apoptosis path-
way was activated after transfection of SM22a into LNCaP cells and
interaction between SM22a and p53 was conﬁrmed by co-immu-
noprecipitation in these cells [25]. SM22a has been also suggestedcells exposed to hypoxic conditions (1% O2, 24 h) were analyzed by Western blot of
nalyzed in SM22a-overexpressing A549 cells at 72 h or 96 h post-transfection. (C)
, and then analyzed on the status of IGF1Rb and Akt phosphorylation. (D) An SM22a
h and the cells were analyzed by Western blot for phosphorylated IGF1Rb and Akt.
Fig. 5. SM22a in hypoxic A549 cells co-immunoprecipitates with IGF1Rb. Immunoprecipitates with anti-IGF1Rb antibody from (A) SM22a-overexpressing cells, (B)
SM22amut- expressing cells, or (C) hypoxic A549 cells were analyzed by Western blot with anti-SM22a or anti-IGF-1Rb antibodies. Immunoprecipitates with anti-EGFR or
rabbit IgG were used as non-speciﬁc controls for immunoprecipitation. Cells un-transfected or in normoxia were used as controls for Western blot. 20 lg of total cell lysate
was loaded in each lane and analyzed.
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sion is lost in prostate, breast, colon, and lung cancer [10,26],
which is consistent with SM22a-mediated suppression of MMP-9
[27]. In recent studies, we demonstrated SM22a as an inducer of
cellular resistance to cytotoxic drugs or radiation. SM22a-over-
expressing HepG2 cells became resistant to apoptotic cell death
caused by cytotoxic agents, in which metallothionein isoforms,
especially MT1G, were signiﬁcantly induced [11]. These cells were
in a state of growth arrest and showed elevated p16INK4a followed
by pRB activation, which promotes cellular senescence caused by
treatment with a subclinical dose of gamma-radiation or doxorubi-
cin [12]. SM22a overexpression in HepG2 cells also inhibited the
activation of IGF1Rb/Akt and extracellular signal-regulated kinase,
thereby suppressing cell proliferation [11].
Here, we examined the functions of SM22a associated with
chemo- or radiation-resistance in NSCLC cells, where multi-drug
chemotherapy resistance is an obstacle to cancer treatment [17].
Similar to HepG2 cells, cytotoxic drugs induce SM22a in A549
NSCLC cells, in which basal SM22a expression is very low.
SM22a-overexpressing A549 cells exhibit dramatic resistance to
anticancer drugs and gamma-radiation. More importantly, we have
demonstrated that hypoxic conditions, which can be a direct cause
of therapeutic resistance [17], also elevate SM22a expression in a
HIF-1a-independent manner. However, the mechanism of how
SM22a induces chemo-resistance in A549 cells seems to be differ-
ent from that in HepG2 cells. SM22a-overexpression in HepG2
cells induces growth arrest and inhibits IGF1Rb/Akt activation.
On the contrary, in A549 NSCLC cells, SM22a overexpression en-
hances cell growth and IGF1Rb auto-phosphorylation, which is
mediated by direct interaction of SM22a with IGF1Rb. Schnizer
et al. reported that hypoxia protects A549 cells from drug-induced
apoptosis [18]. They also suggested that cell protection mecha-
nisms under hypoxic conditions are HIF-dependent or -indepen-
dent. Here, we suggest that SM22a is an important factor in HIF-
independent hypoxic response of A549 cells and is a novel regula-
tor of IGF1Rb activation.
Patients with NSCLC exhibit advanced disease and their resis-
tance to chemo- or radiotherapy makes cancer treatment less
effective. In addition, patient’s responses to these cancer therapies
vary, which makes predictive biomarkers for therapeutic response
be an important facet of personalized medicine. In this aspect, it
might be an important factor for decision of cancer therapy
whether SM22a is induced by chemical or radiation treatment.Also, if a medical treatment can be developed that can modulate
SM22a expression during hypoxia or aggressive lung cancer, the
efﬁciency of cancer therapy will be improved.
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